Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 181Colorectal Neoplasms 144Stomach Neoplasms 90Rectal Neoplasms 90Pancreatic Neoplasms 74Neoplasm Metastasis 60Neoplasms 48Colonic Neoplasms 40Esophageal Neoplasms 31Gallbladder Neoplasms 18Biliary Tract Neoplasms 17Bile Duct Neoplasms 17Carcinoma, Hepatocellular 15Triple Negative Breast Neoplasms 13Cholangiocarcinoma 12Adenocarcinoma 12Unspecified Adult Solid Tumor, Protocol Specific 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Liver Neoplasms 10Breast Neoplasms, Male 10Adenocarcinoma Of Esophagus 10Squamous Cell Carcinoma of Head and Neck 9Head and Neck Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mid-low Rectal Cancer × Capecitabine × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡